Cidara Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 69
- Market Cap
- -
- Website
- http://www.cidara.com
- Introduction
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Clinical Trials
30
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388
- Conditions
- Healthy Participants
- First Posted Date
- 2025-11-10
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT07225959
- Locations
- πΊπΈ
Floridian Clinical Research, Miami Lakes, Florida, United States
πΊπΈSpartanburg Medical Research, Spartanburg, South Carolina, United States
π¬π§hVIVO Serviced Limited, London, England, United Kingdom
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
- Conditions
- Influenza
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 6000
- Registration Number
- NCT07159763
- Locations
- π¬π§
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital, Leeds, England, United Kingdom
π¬π§Windrush Medical Practice, Witney, England, United Kingdom
πΊπΈPinnacle Research Group, LLC, Anniston, Alabama, United States
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
- Conditions
- Influenza
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 5071
- Registration Number
- NCT06609460
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈCullman Clinical Trials, Cullman, Alabama, United States
πΊπΈFiel Family and Sports Medicine/CCT Research, Tempe, Arizona, United States
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
- Conditions
- Healthy
- Interventions
- Combination Product: CD388 InjectionDrug: Saline placebo
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05619536
- Locations
- πΊπΈ
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
- Conditions
- Influenza
- Interventions
- Drug: Saline placeboCombination Product: CD388
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT05523089
- Locations
- π¬π§
hVIVO Services Limited, London, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
Long-Acting Antiviral CD388 Shows 76% Efficacy Against Flu in Phase 3 Trial
A single injection of CD388, a modified zanamivir antiviral, demonstrated 76% efficacy in preventing symptomatic flu infections in a 5,000-participant Phase 3 trial.